Stelis Biopharma, a vertically integrated biopharma and vaccines company and the biotech arm of Strides Pharma Science, has announced the appointment of Mark W. Womack as CEO.
Womack is also the MD designate and will be inducted to the board, subject to necessary statutory clearances and processes. As CEO and MD, Womack will provide leadership to drive an aggressive growth strategy for the company in its business streams, including global CDMO services and the development of the company's biosimilars pipeline, and integrated vaccines play. He will be responsible for the company's overall strategy and provide direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations.
Commenting on the development, Arun Kumar, founder, Strides Group, said: "We are delighted to onboard Mark as the new CEO of Stelis. Stelis stands on the cusp of a transition to become a globally recognised biopharmaceutical company while targeting significant growth in the coming years. Mark's strong background in commercial leadership, rich management consulting experience, and network within the biotech CDMO space make him exceptionally well suited to drive this transition for Stelis. We are confident that together Mark and his leadership team will take Stelis through the next level of growth, profitability and industry-leading reputation."
Before joining Stelis, Womack was the Chief Business Officer for AGC Biologics. In his role at AGC, Womack led the organisation to nearly a threefold increase in new sales in two years and drove the acquisition of top pharma companies into its portfolio. Before that, he led the integration of three former CDMOs that were merged to create AGC Biologics.
Womack has served over 25 years as a management consulting industry leader and C-level client advisor. During this time, he served as the COO for two international management consulting companies.